Current Nutrition Reports

, Volume 3, Issue 4, pp 364–378 | Cite as

Prevention of Diabetes Through Lifestyle Intervention: Lessons Learned from the Diabetes Prevention Program and Outcomes Study and its Translation to Practice

  • Mary A. HoskinEmail author
  • George A. Bray
  • Kathy Hattaway
  • Prajakta A. Khare-Ranade
  • Jeremy Pomeroy
  • Linda N. Semler
  • Valarie A. Weinzierl
  • Judith Wylie-Rosett
  • for the Diabetes Prevention Program Research Group
Public Health and Translational Medicine (PW Franks, Section Editor)


A number of strategies have been used to delay or prevent the development of type 2 diabetes mellitus (T2D) in high-risk adults, such as diet, exercise, medications, and surgery. This report focuses on the nutritional lessons learned from implementation of the Intensive Lifestyle Intervention (ILI) in the DPP and its follow-up DPPOS that looked at weight loss through modification of diet and exercise. The Diabetes Prevention Program (DPP) is a large clinical trial, sponsored by the National Institutes of Health, designed to look at several strategies to prevent conversion to type 2 diabetes (T2D) by adults with prediabetes (IGT/IFG), including ILI. The ~3800 ethnically diverse participants (46 % reported nonwhite race) were overweight, had impaired glucose tolerance (IGT), and impaired fasting glucose (IFG). Treatments were assigned randomly. The Diabetes Prevention Program Outcomes Study (DPPOS) is a follow-up study that evaluated the long-term outcomes of the clinical trial.

Trial registration: DPP is registered in (NCT00004992) and DPPOS (NCT 00038727).


Lifestyle intervention Diabetes prevention Weight loss Physical activity Prevention Diabetes Overweight Type 2 diabetes Nutrition Lifestyle Diet Genetics 



The Research Group gratefully acknowledges the commitment and dedication of the participants of the DPP and DPPOS. During the DPPOS, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health provided funding to the clinical centers and the Coordinating Center for the design and conduct of the study, and collection, management, analysis, and interpretation of the data. The Southwestern American Indian Centers were supported directly by the NIDDK, including its Intramural Research Program, and the Indian Health Service. The General Clinical Research Center Program, National Center for Research Resources, and the Department of Veterans Affairs supported data collection at many of the clinical centers. Funding also was provided by the National Institute of Child Health and Human Development, the National Institute on Aging, the National Eye Institute, the National Heart Lung and Blood Institute, the Office of Research on Women’s Health, the National Institute on Minority Health and Health Disparities, the Centers for Disease Control and Prevention, and the American Diabetes Association. Bristol-Myers Squibb and Parke-Davis provided additional funding and material support during the DPP, Lipha (Merck-Sante) provided medication and LifeScan Inc. donated materials during the DPP and DPPOS. The opinions expressed are those of the investigators and do not necessarily reflect the views of the funding agencies. A complete list of centers, investigators, and staff can be found in the Appendix.

Compliance with Ethics Guidelines

Conflict of Interest

Mary A. Hoskin declares that she has no conflict of interest.

George A. Bray has received research support through a grant from the NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); has received compensation from Herbalife Nutrition Institute, Jason Pharmaceuticals, and Theracos Pharmaceuticals for service as a consultant; has received payment for lectures including service on speakers bureaus from the American Association of Clinical Endocrinologists; and has received royalties from contributions to the Handbook of Obesity, Up-to-Date, and CRC Press.

Kathy Hattaway declares that she has no conflict of interest.

Prajakta A. Khare-Ranade declares that she has no conflict of interest.

Jeremy Pomeroy declares that he has no conflict of interest.

Linda N. Semler has been issued a patent for the Group Lifestyle Balance™ program, but has disclaimed rights to licensing proceeds and has no personal financial interest in the licensing for the program.

Valarie A. Weinzierl declares that she has no conflict of interest.

Judith Wylie-Rosett has received research support through a grant from the NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for the Einstein-Sinai Diabetes Research Center and for DPP translation.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Crandall JP, Knowler WC, Kahn SE, Marrero D, Florez JC, Bray GA, et al. The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab. 2008;4(7):382–93.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.PubMedCrossRefGoogle Scholar
  3. 3.
    Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Haffman HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;14(374):1677–86.Google Scholar
  4. 4.
    The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999;22(4):623–34.CrossRefGoogle Scholar
  5. 5.
    Diabetes Prevention Program Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002;25(12):2165–71.CrossRefGoogle Scholar
  6. 6.••
    The Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care. 2012;35(4):723–30. The DPP and its Outcomes study demonstrated that both ILI and metformin could prevent diabetes in those at high risk for at least 10 years post-randomization and this investment provides good value for funds invested in prevention. These data are important for building meaningful translation of diabetes prevention strategies.PubMedCentralCrossRefGoogle Scholar
  7. 7.
    Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183–97.Google Scholar
  8. 8.
    Mayer-Davis EJ, Sparks KC, Hirst K, et al. Dietary intake in the Diabetes Prevention Program cohort: baseline and 1 year post randomization. Ann Epidemol. 2004;14(10):763–72.CrossRefGoogle Scholar
  9. 9.••
    Jaacks LM, Ma Y, Davis N, Delahanty LM, Mayer-Davis EJ, Franks PW, et al. Long-term changes in dietary intake and food behaviors in the Diabetes Prevention Program Outcomes Study. Diabet Med. 2014. doi: 10.1111/dme.12500. This analysis was of long term changes in food intake and diet-related behaviors in the DPP. Significant differences remained between randomized groups up to 9 years.PubMedGoogle Scholar
  10. 10.••
    Davis NJ, Ma Y, Delahanty LM, Hoffman HJ, Mayer-Davis E, Franks PW, et al. Predictors of sustained reduction in energy and fat intake in the Diabetes Prevention Program Outcomes Study intensive lifestyle intervention. J Acad Nutr Diet. 2013;113(11):1455–64. The DPP’s Intensive Lifestyle Intervention resulted in reductions of total energy intake for up to 9 years. Initial success at goal achievement predicted long-term success at maintaining changes achieved.PubMedCrossRefGoogle Scholar
  11. 11.
    Kriska AM, Edelstein SL, Hamman RF, Otto A, Bray GA, Mayer-Davis EJ, et al. Physical activity in individuals at risk for diabetes: Diabetes Prevention Program. Med Sci Sports Exerc. 2006;38(5):826–32.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Delahanty L, Begay S, Cooeyate N, Hoskin M, Isonaga M, Levy E, et al. The effectiveness of lifestyle intervention in the Diabetes Prevention Program: application in diverse ethnic groups. Cutting Edge 2002;23(6):30–6.
  13. 13.
    Hoskin M, Begay S, Bolin P, Hermes J, Ingraham L, Killean T, et al. Providing lifestyle interventions in American Indian communities. Obes Manag J. 2005;1(6):251–5.CrossRefGoogle Scholar
  14. 14.
    Wylie-Rosett J, Delahanty L. An integral role of the dietitian: implications of the Diabetes Prevention Program. J Am Diet Assoc. 2002;102(8):1065–8.PubMedCentralPubMedGoogle Scholar
  15. 15.••
    Venditti E, Wylie-Rosett J, Delahanty L, Mele L, Hoskin M, Edelstein S, et al. Short and long-term lifestyle coaching approaches used to address diverse participant barriers to weight loss and physical activity adherence. Int J Behav Nutr Phys Act. 2014;11(1):16. The coaching approaches that were critical to the success of the DPP Intensive Lifestyle Intervention are analyzed and reviewed here. This is a critical piece to the implementation of the highly effective intervention.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29(9):2102–7.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.•
    Maruthur NM, Ma Y, Delahanty LM, Nelson JA, Aroda V, White NH, et al. Early response to preventive strategies in the Diabetes Prevention Program. J Gen Intern Med. 2013;28(12):1629–36. These researchers looked at what predicts reduced diabetes risk; weight and glucose at 6 and 12 months.PubMedCrossRefGoogle Scholar
  18. 18.
    Ratner RE, Chitson PA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab. 2008;93(12):4774–9.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.••
    Sullivan SD, Jablonski KA, Florez JC, Dabelea D, Franks PW, Dagogo-Jack S, et al. Genetic risk of progression to type 2 diabetes and response to intensive lifestyle or metformin in prediabetic women with and without a history of gestational diabetes. Diabetes Care. 2014;37(4):909–11. These data suggest that diabetes-associated GRS is associated with the development of GDM due to reduced beta cell function but did not predict progression to diabetes or modulate the response to the interventions.PubMedCrossRefGoogle Scholar
  20. 20.
    Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care. 2005;28(4):888–94.PubMedCrossRefGoogle Scholar
  21. 21.
    Goldberg RB, Temprosa M, Haffner S, Orchard TJ, Ratner RE, Fowler SE, et al. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: for the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care. 2009;32(4):726–32.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.••
    Orchard TJ, Temprosa M, Barrett-Connor E, Fowler S, Goldberg R, Mather K, et al. Long term effects of the Diabetes Prevention Program’s interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med. 2013;30(1):46–55. CVD risk reduction is important to evaluate when looking at methods to prevent diabetes. In the DPP and DPPOS, the Intensive Lifestyle Intervention achieved, with fewer medications, a comparable CVD risk reduction as the other treatment groups.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Goldberg RB, Temprosa M, Otvos J, Brunzell J, Marcovina SM, Mather KJ, et al. Lifestyle and metformin treatment favorably influence lipoprotein sub-fraction distribution in the Diabetes Prevention Program. J Clin Endocrinol Metab. 2013;98(10):3989–98.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142(8):611–9.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.••
    Florez H, Temprosa MG, Orchard TJ, Mather KJ, Marcovina SM, Barrett-Connor E, et al. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes Obes Metab. 2013;16(4):326–33. The researchers associated MetS and its components with diabetes risk in DPP participants, all of whom had IGT at baseline. They then assessed the intervention-related changes in the components of MetS and their correlations with the development of T2D.PubMedCrossRefGoogle Scholar
  26. 26.
    Bray GA, Fujimoto W, Jablonski K, Barrett-Connor E, Haffner S, Hubbard V, et al. Relationship of body size and shape to the development of diabetes in the Diabetes Prevention Program. Obesity (Silver Spring). 2006;14(11):2107–17.CrossRefGoogle Scholar
  27. 27.
    Fujimoto WY, Jablonski KA, Bray GA, Kriska A, Barrett-Connor E, Haffner S, et al. Body size and shape changes and the risk of diabetes in the Diabetes Prevention Program. Diabetes. 2007;56(6):1680–5.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Wing RR, Hamman RF, Bray GA, Delahanty L, Edelstein SL, Hill JO, et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obes Res. 2004;12(9):1426–34.PubMedCrossRefGoogle Scholar
  29. 29.
    Venditti EM, Bray GA, Carrion-Petersen ML, Delahanty LM, Edelstein SL, Hamman RF, et al. First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcome. Int J Obes (Lond). 2008;32(10):1537–44.CrossRefGoogle Scholar
  30. 30.
    Price DW, Ma Y, Rubin RR, Perreault L, Bray GA, Marrero D, et al. Depression as a predictor of weight regain among successful weight losers in the Diabetes Prevention Program. Diabetes Care. 2013;36(2):216–21.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Rubin RR, Ma Y, Peyrot M, Marrero DG, Price DW, Barrett-Connor E, et al. Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study. Diabetes Care. 2010;33(12):2549–51.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Rubin RR, Knowler WC, Ma Y, Marrero DG, Edelstein SL, Walker EA, et al. Depression symptoms and antidepressant medicine use in Diabetes Prevention Program participants. Diabetes Care. 2005;28(4):830–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Diabetes Prevention Program Research Group, Crandall J, Schade D, Ma Y, Fujimoto WY, Barrett-Connor E, et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci. 2006;61(10):1075–81.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Ratner R, Diabetes Prevention Program Research Group. An update on the Diabetes Prevention Program. Endocr Pract. 2006;12 Suppl 1:20–4.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Brown JS, Wing R, Barrett-Connor E, Nyberg LM, Kusek JW, Orchard TJ, et al. Lifestyle intervention is associated with lower prevalence of urinary incontinence: the Diabetes Prevention Program. Diabetes Care. 2006;29(2):385–90.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes. 2005;54(5):1566–72.PubMedCrossRefGoogle Scholar
  37. 37.
    Hivert M-F, Jablonski KA, Perreault L, Saxena R, McAteer JB, Franks PW, et al. Updated genetic score based on 34 confirmed type 2 diabetes loci is associated with diabetes incidence and regression to normoglycemia in the Diabetes Prevention Program. Diabetes. 2011;60:1340–8.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Herman WH, Hoerger TJ, Brandle M, Diabetes Prevention Program Research Group, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142(5):323–32.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.••
    Herman WH, Edelstein SL, Ratner RE, The Diabetes Prevention Program Research Group, et al. Effectiveness and cost – effectiveness of diabetes prevention among adherent participants. Am J Manag Care. 2013;19(3):194–202. The analysis of cost-effectiveness of the DPP and DPPOS treatment groups for those participants who were adherent to the treatments revealed that the treatments were cost saving or cost effective compared with placebo. Costs for individual and group classes were analyzed. These treatments to prevent diabetes represent a good value for the cost.PubMedCentralPubMedGoogle Scholar
  40. 40.
    Simmons RK, Unwin N, Griffin SJ. International Diabetes Federation: an update of the evidence concerning the prevention of type 2 diabetes. Diabetes Res Clin Pract. 2010;87(2):143–9.PubMedCrossRefGoogle Scholar
  41. 41.•
    Ali MK, Echouffo-Tcheugui J, Williamson DF. How effective were lifestyle interventions in real-world settings that were modeled on the diabetes prevention program? Health Aff. 2012;31:67–75. They evaluated the effectiveness of 28 US-based studies applying the DPP ILI for people at high risk of T2D. Change in weight was about 4% of initial body weight and these results were similar in programs that delivered the intervention utilizing clinically trained professionals or lay educators.CrossRefGoogle Scholar
  42. 42.•
    Aguiar EJ, Morgan PJ, Collins CE, Plotnikoff RC, Callister R. Efficacy of interventions that include diet, aerobic and resistance training components for type 2 diabetes prevention: a systematic review with meta-analysis. Int J Behav Nutr Phys Act. 2014;11:2. These authors evaluated the efficacy and effectiveness of interventions that include diet, with both aerobic and resistance training, in behavioral weight loss programs designed to prevent diabetes.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.•
    Dunkley AJ, Bodicoat DH, Greaves CJ, Russell C, Yates T, Davies MJ, et al. Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis. Diabetes Care. 2014;37:922–33. A meta-analysis of 22 studies detailing the success of the translation the studies they reviewed. These programs were effective at achieving weight loss, with greater adherence to guidelines resulting in significantly greater weight loss.PubMedCrossRefGoogle Scholar
  44. 44.
    Paulweber B, Valensi P, Lindström J, et al. A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res. 2010;42 Suppl 1:S3–36.PubMedCrossRefGoogle Scholar
  45. 45.
    National Institute for Health and Clinical Excellence. Preventing type 2 diabetes: risk identification and interventions for individuals at high risk. London: National Institute for Health and Clinical Excellence; 2012.Google Scholar
  46. 46.•
    Merlotti C, Morabito A, Pontiroli AE. Prevention of type 2 diabetes; a systematic review and meta-analysis of different intervention strategies. Diabetes Obes Metab. 2014. This review looked at interventions that used 15 different strategies to prevent T2D. Age of subject and amount of weight lost was related to the effectiveness of the interventions.Google Scholar
  47. 47.•
    Sumamo Schellenberg E, Dryden DM, Vandermeer B, Ha C, Korownyk C. Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(8):543–51. Randomized clinical trials were identified that were of at least 3 months duration, included diet and exercise and at least one other component aimed at preventing T2D. Seven studies reported that lifestyle interventions decreased the risk for diabetes from the end of intervention up to 10 years after it. They concluded that comprehensive lifestyle interventions that include these components are effective in decreasing incidence of T2D in high risk patients and the benefit extends beyond the active intervention phase.CrossRefGoogle Scholar
  48. 48.
    Yuen A, Sugeng Y, Weiland TJ, Jelani GA. Lifestyle and medication interventions for the prevention or delay of type 2 diabetes mellitus in prediabetes: a systematic review of randomised controlled trials. Aust N Z J Public Health. 2010;34(2):172–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Whittemore R. A systematic review of the translational research on the Diabetes Prevention Program. Transl Behav Med. 2011;1(3):480–91.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.•
    Ruggiero L, Castillo A, Quinn L, Hochwert M. Translation of the diabetes prevention program’s lifestyle intervention: role of community health workers. Curr Diab Rep. 2012;12(2):127–37. Many underserved communities affected by high rates of T2D have access to a health system that include Community Health Workers. This article provides an overview of studies involving these workers in prevention of T2D.PubMedCrossRefGoogle Scholar
  51. 51.
    Kramer MK, Kriska AM, Venditti EM, Miller RG, Brooks MM, Burke LE, et al. Translating the Diabetes Prevention Program: a comprehensive model for prevention training and program delivery. Am J Prev Med. 2009;37(6):505–11.PubMedCrossRefGoogle Scholar
  52. 52.
    Venditti E, Kramer M. Diabetes Prevention Program community outreach perspectives on lifestyle training and translation. Am J Prev Med. 2013;44:S339–45.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.•
    Luohua J, Spero MM, Janette B, William HG, Haixiao H, Kelly AJ, et al. Translating the Diabetes Prevention Program into American Indian and Alaska native communities. Diabetes Care. 2013;36(9):2027–34. Type 2 diabetes affects American Indians disproportionately, and in 2009 was twice the age-adjusted prevalence of non-Hispanic whites. Effective translation of the DPP into Native Communities with scarce resources and diverse health care settings and a highly mobile population will have an important positive impact.Google Scholar
  54. 54.
    Vojta D, Koehler T, Longjohn M, Lever J, Caputo N. A coordinated national model for diabetes prevention: linking health systems to an evidence-based community program. Am J Prev Med. 2013;44:S301–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York (outside the USA) 2014

Authors and Affiliations

  • Mary A. Hoskin
    • 1
    • 8
    Email author
  • George A. Bray
    • 2
  • Kathy Hattaway
    • 3
  • Prajakta A. Khare-Ranade
    • 4
  • Jeremy Pomeroy
    • 5
  • Linda N. Semler
    • 6
  • Valarie A. Weinzierl
    • 6
  • Judith Wylie-Rosett
    • 7
  • for the Diabetes Prevention Program Research Group
  1. 1.American Indian Professional Services, Inc.ACKCOPhoenixUSA
  2. 2.Pennington Biomedical CenterLouisiana State UniversityBaton RougeUSA
  3. 3.University of TexasSan AntonioUSA
  4. 4.Washington UniversitySt LouisUSA
  5. 5.Phoenix Epidemiology and Clinical Research BranchNIDDKPhoenixUSA
  6. 6.University of PittsburghPittsburghUSA
  7. 7.Albert Einstein College of MedicineBronxUSA
  8. 8.Diabetes Prevention Program Coordinating Center, The Biostatistics CenterGeorge Washington UniversityRockvilleUSA

Personalised recommendations